Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

arGEN-X and de Duve Institute/UCL sign collaboration to develop immunomodulation therapy for cancer

Nov. 5, 2013

Farletuzumab misses phase II endpoint for NSCLC

Nov. 5, 2013

SymBio and Eisai discontinue Japanese phase II trial of Treakisym

Nov. 4, 2013

OncoMed Pharmaceuticals begins phase Ib trial of vantictumab with paclitaxel

Oct. 30, 2013

Vaccine targeting IDO safe and well tolerated in first-in-human study

Oct. 29, 2013

Mologen files application in Belgium to conduct trial in small cell lung cancer

Oct. 29, 2013

FDA grants orphan drug designation to Aduro's immunotherapy for pancreatic cancer

Oct. 23, 2013

Antibody DCBPR-01101 targets globo H for breast cancer treatment

Oct. 23, 2013

Updated immunological results published from phase I evaluation of AE37 prostate cancer vaccine

Oct. 23, 2013

FDA submission for Arzerra in previously untreated CLL

Oct. 22, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...